

## Special Issue

# The Molecular and Cellular Biology of Neuroprotection

### Message from the Guest Editors

Neurological disorders are a significant global health issue with complex etiologies and pathophysiology. Neuroprotection describes strategies that protect, mitigate, or delay neuronal damage by intervening and inhibiting processes that cause neuronal dysfunction, or those that promote wound healing. Common mechanisms of neuronal injury include excitotoxicity, neuroinflammation, decreased delivery of oxygen and glucose, increased oxidative stress, mitochondrial dysfunction, cellular energy failure, iron accumulation, or protein misfolding and aggregation. A better understanding of these processes in terms of their molecular and cellular biology will promote translational research and therefore aid in the designing of new therapeutic strategies.

This Special Issue aims to present the most up-to-date findings regarding research targeting the mechanisms underlying different neurological disorders and neuroprotection strategies. It aims to provide a broad overview of novel advances in the field.

### Guest Editors

Dr. Elisa Martín-Montañez

1. Department of Pharmacology, Faculty of Medicine, Campus Teatinos, University of Malaga, 29010 Malaga, Spain
2. Institute of Biomedical Research of Malaga (IBIMA), 29010 Malaga, Spain

Dr. Silvana Yanina Romero-Zerbo

1. Department of Human Physiology, Faculty of Medicine, Campus Teatinos, University of Malaga, 29010 Malaga, Spain
2. Institute of Biomedical Research of Malaga (IBIMA), 29010 Malaga, Spain

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/142697](https://mdpi.com/si/142697)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).